Optimal timing and dosing intervals of palivizumab in premature neonates: still some work to do

Pediatrics. 2005 May;115(5):1439-40; author reply 1440-1. doi: 10.1542/peds.2004-2865.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / blood
  • Antibodies, Monoclonal, Humanized
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Humans
  • Infant, Newborn
  • Infant, Premature / blood
  • Infant, Premature, Diseases / prevention & control*
  • Palivizumab
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Viruses

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Palivizumab